1-indol-3-yl-2-methylamino-ethanol | 28755-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-indol-3-yl-2-methylamino-ethanol
• 英文别名: 1-Indol-3-yl-2-methylamino-aethanol；1-(1H-indol-3-yl)-2-(methylamino)ethanol
• CAS: 28755-00-2
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: FLDZGFXKYUCKRH-UHFFFAOYSA-N

物化性质

• 沸点：
  410.2±30.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  48
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-indol-3-yl-2-methylamino-ethanol 在 吡啶 作用下， 以 水 为溶剂， 生成 [(2S,3R)-2,3-diacetyloxy-4-[(3S,4R)-3-hydroxy-4-(1H-indol-3-yl)-1-methyl-2-oxopyrrolidin-3-yl]-4-oxobutyl] acetate
  参考文献：
  名称：

  Interaction of L-Ascorbic Acid with DL-N-Methyl-β-hydroxytryptamine

  摘要：

  The interaction of DL-N-methyl-beta-hydroxytryptamine 1 with L-ascorbic acid 2 proceeds through the 2-C alkylation of 2 and the intramolecular acylation of the methylamino group to yield diastereomeric 3-hydroxy-4-(indol-3-yl)-1-methyl-3-(2,3,4-trihydroxybutyryl)pyrrolid-2-one 4a and 5b. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(97)10461-0
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 palladium on activated charcoal 、 乙醇 作用下， 生成 1-indol-3-yl-2-methylamino-ethanol
  参考文献：
  名称：

  Ames et al., Journal of the Chemical Society, 1956, p. 1984,1988

  摘要：

  DOI：

文献信息

• Antiviral agents
  申请人：——

  公开号：US20040138449A1

  公开（公告）日：2004-07-15

  The invention provides a compound of formula I: 1 wherein G, R 2 , and R 3 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.

  本发明提供了一种公式I的化合物： 1 其中G，R 2 ，和R 3 具有规范中定义的任何值，或其药用可接受盐，以及用于制备该化合物或盐的有用过程和中间体，以及使用该化合物或盐治疗疱疹病毒感染的方法。
• 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: Synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase
  作者：Scott D. Larsen、Zhijun Zhang、Brian A. DiPaolo、Peter R. Manninen、Douglas C. Rohrer、Michael J. Hageman、Todd A. Hopkins、Mary L. Knechtel、Nancee L. Oien、Bob D. Rush、Francis J. Schwende、Kevin J. Stefanski、Janet L. Wieber、Karen F. Wilkinson、Kathyrn M. Zamora、Michael W. Wathen、Roger J. Brideau

  DOI：10.1016/j.bmcl.2007.05.010

  日期：2007.7

  We report a new class of non-nucleoside antivirals, the 7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides, some of which possess remarkable potency versus a broad spectrum of herpesvirus DNA polymerases and excellent selectivity compared to human DNA polymerases. A critical factor in the level of activity is hypothesized to be conformational restriction of the key 2-aryl-2-hydroxyethylamine sidechain

  我们报告了一种新型的非核苷类抗病毒药，即7-氧代-4,7-二氢噻吩并[3,2-b]吡啶-6-羧酰胺，其中一些具有显着的效力，与广谱的疱疹病毒DNA聚合酶相比，具有出色的杀伤力。与人类DNA聚合酶相比具有更高的选择性。假定活性水平中的关键因素是关键的2-芳基-2-羟基乙胺侧链被相邻的甲基构象限制。
• ANTIVIRAL COMPOUNDS
  申请人：——

  公开号：US20040242884A1

  公开（公告）日：2004-12-02

  The invention provides a compound of formula I: 1 wherein G, R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpes virus infection using such compounds or salts.

  本发明提供了一种I式化合物：1，其中G，R2，R3和R4具有规范中定义的任何值，或其药学上可接受的盐，以及用于制备这种化合物或盐的有用中间体和过程，以及使用这种化合物或盐预防或治疗疱疹病毒感染的方法。
• Antiviral compounds
  申请人：Larsen Scott D.

  公开号：US06852731B2

  公开（公告）日：2005-02-08

  The invention provides a compound of formula I: wherein G, R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

  该发明提供了化合物I的公式：其中G，R2，R3和R4具有规范中定义的任何值或其药学上可接受的盐，以及用于制备这样的化合物或盐的中间体和过程，以及使用这样的化合物或盐预防或治疗疱疹病毒感染的方法。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。